Want to see DE:COP full AI Analyst Report?
Top Page
CompuGroup Medical
(Hamburg:COP)
Select Model
Select Model
Rating:60Neutral
Price Target:
€28.00
▲(18.54% Upside)
Action:Reiterated
Date:10/22/25
CompuGroup Medical's overall stock score is driven by stable financial performance and operational efficiency. However, high valuation metrics and technical indicators suggest caution. The lack of earnings call data and corporate events limits additional insights.
Positive Factors
Recurring SaaS and diversified revenue streams
A mixed model of one‑time license sales plus subscription and cloud SaaS creates recurring revenue and higher customer lifetime value. This durability improves predictability, supports retention and upsell, and underpins multi‑year cash flow visibility for reinvestment and debt servicing.
Negative Factors
Moderate leverage and reliance on debt financing
A moderate debt load reduces financial flexibility and raises sensitivity to interest costs and refinancing cycles. Over a multi‑month horizon this can constrain strategic moves, limit opportunistic M&A, and force prioritization of cash to debt service rather than growth or shareholder distributions.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring SaaS and diversified revenue streams
A mixed model of one‑time license sales plus subscription and cloud SaaS creates recurring revenue and higher customer lifetime value. This durability improves predictability, supports retention and upsell, and underpins multi‑year cash flow visibility for reinvestment and debt servicing.
Read all positive factors
CompuGroup Medical (COP) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.43B
Dividend Yield0.2%
Average Volume (3M)3.83K
Price to Earnings (P/E)43.4
Beta (1Y)0.34
Revenue Growth1.16%
EPS Growth-43.53%
CountryDE
Employees8,299
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.59
Shares Outstanding53,734,577
10 Day Avg. Volume3,449
30 Day Avg. Volume3,827
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.89
Revenue Forecast (FY)€1.21B
CompuGroup Medical Business Overview & Revenue Model
Company Description
CompuGroup Medical (COP) is a leading global eHealth company that provides software solutions for healthcare providers, including hospitals, practices, and pharmacies. The company operates primarily in the healthcare IT sector, offering a wide ran...
How the Company Makes Money
CompuGroup Medical generates revenue through multiple streams, primarily by selling software licenses and providing subscription-based services to healthcare providers. Their core revenue model includes one-time fees for software licenses, ongoing...
CompuGroup Medical Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
65
Positive
Cash Flow
75
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.16B | 1.15B | 1.19B | 1.13B | 1.03B | 837.26M |
| Gross Profit | 821.16M | 965.14M | 1.01B | 958.16M | 285.89M | 712.95M |
| EBITDA | 197.37M | 206.90M | 215.84M | 231.36M | 216.63M | 192.49M |
| Net Income | 27.00M | 34.60M | 45.92M | 73.41M | 68.97M | 73.19M |
Balance Sheet | ||||||
| Total Assets | 2.02B | 1.97B | 1.90B | 1.94B | 1.79B | 1.57B |
| Cash, Cash Equivalents and Short-Term Investments | 128.64M | 107.61M | 64.54M | 90.96M | 107.63M | 75.61M |
| Total Debt | 826.65M | 879.99M | 766.94M | 786.47M | 741.31M | 554.54M |
| Total Liabilities | 1.37B | 1.32B | 1.23B | 1.27B | 1.18B | 926.84M |
| Stockholders Equity | 651.09M | 647.91M | 667.68M | 672.42M | 612.07M | 638.67M |
Cash Flow | ||||||
| Free Cash Flow | 84.57M | 65.66M | 104.11M | 63.99M | 87.78M | 94.20M |
| Operating Cash Flow | 143.96M | 128.88M | 179.53M | 145.03M | 165.27M | 149.93M |
| Investing Cash Flow | -108.83M | -105.28M | -124.33M | -145.41M | -163.98M | -457.12M |
| Financing Cash Flow | -35.70M | 18.81M | -80.69M | -16.36M | 30.15M | 338.07M |
CompuGroup Medical Technical Analysis
Neutral
23.62
Price Trends
27.23
Negative
26.88
Positive
25.54
Positive
Market Momentum
<0.01
Positive
48.24
Neutral
38.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:COP, the sentiment is Neutral. The current price of 23.62 is below the 20-day moving average (MA) of 27.40, below the 50-day MA of 27.23, and below the 200-day MA of 25.54, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 38.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:COP.
CompuGroup Medical Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €42.95M | 17.88 | 13.45% | 3.86% | -6.92% | -67.82% | |
69 Neutral | €3.88B | 16.39 | 11.74% | 1.62% | 4.04% | 4.21% | |
68 Neutral | €58.35M | 10.95 | 13.28% | 6.36% | 2.84% | 0.96% | |
66 Neutral | €2.44B | 20.07 | 6.69% | 1.50% | -0.06% | -38.81% | |
60 Neutral | €1.43B | 43.42 | 4.19% | 0.20% | 1.16% | -43.53% | |
56 Neutral | €321.51M | 13.10 | 12.82% | 0.85% | 13.29% | 214.17% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
DE:COP
CompuGroup Medical
27.20
4.09
17.68%
DE:ADN1
adesso AG
51.70
-35.95
-41.02%
DE:BC8
Bechtle Aktiengesellschaft
31.22
-7.67
-19.73%
DE:AFX
Carl Zeiss Meditec
26.60
-29.15
-52.28%
DE:M3V
MeVis Medical Solutions
24.20
0.49
2.08%
DE:AJ91
DocCheck AG
11.50
0.66
6.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.